Received May 02, 2016; Accepted May 13, 2016; Published May 17, 2016
Citation: Wright JW, Harding JW (2016) Small Molecule AngIV-based Analogs to Treat Alzheimer’s Disease. Int J Drug Dev & Res 8:021-027
Alzheimer’s disease (AD) patients are presently without adequate treatment thus new therapeutic approaches are needed to slow and hopefully reverse disease progression. Neurotrophic agents such as nerve growth factor and brain-derived neurotrophic factor have received research attention concerning their potential to treat AD but have not progressed to clinical trials due to their large size, inability to penetrate the blood-brain barrier (BBB), and the high cost of synthesis. This review focuses on one over looked neurotrophin, hepatocyte growth factor (HGF) that acts via the Type 1 tyrosine kinase receptor Met to mediate stem cell differentiation, synaptogenesis, neurogenesis, and protect against tissue insults in a wide range of cell types including neurons. We have determined that the brain angiotensin and HGF/c-Met systems interact in such a way that angiotensin IV (AngIV)-based analogs including Nle1-AngIV, Norleual-AngIV, Dihexa, and others influence HGF dimerization which is a prerequisite to binding at the Met receptor. Several of these analogs have shown the ability to facilitate the formation of new functional synaptic connections in hippocampal slices, promote neurogenesis, and augment memory consolidation and retrieval in animal models of AD. This family of compounds represents a new class of drugs with lead candidates that are orally active, penetrate the BBB sufficiently to reach therapeutic concentrations, and reverse memory deficits seen in animal models of dementia.
Alzheimer’s disease; Angiotensin IV; Nle1-Angiotensin IV; Dihexa; AT4 receptor subtype; Hepatocyte growth factor; Met receptor
Neurodegenerative diseases are characterized by progressive neuron losses in specific brain regions that impact cognitive, sensory and/or motor functioning. These disorders include Alzheimer’s disease (AD), Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s disease. The destructive nature of the damage inflicted by these diseases results in a loss of patient dignity and self-worth and negatively impacts family members and friends. The current number of AD patients in the U.S. is 4.5-5.0 million [1,2] with an estimated 16 million worldwide . Present annual treatment and care costs in the U.S. are $70-100 billion [4,5] and in excess of $600 billion worldwide . De la Torre  has estimated that a treatment that delays the onset of symptoms by 5 years would reduce the number of AD patients by upwards of 50%. Thus, significant efforts are presently directed at designing drugs capable of slowing the progression of disease symptoms, with the ultimate goal of halting and reversing the underlying causes of AD.
The long-standing theory regarding the pathogenesis of AD is the “amyloid cascade hypothesis” [8,9]. This theory assumes that AD is due to the cellular deposition of insoluble amyloid β (Aβ) protein fragments arising from amyloid precursor protein proteolysis. It is suggested that dysfunction between Aβ production and clearance causes damaging accumulations of cellular Aβ, coupled with hyperphosphorylation of neuronal tau protein resulting in neurofibrillary tangle formation [10,11]). Other researchers have proposed that these cellular changes are the result of “chronic cerebral hypoperfusion” facilitated by hypertension, atherosclerosis, diabetes, hypercholesterolemia and aging [11-14]. These clinical disorders can lead to hypoperfusion which in turn results in insufficient oxygen and glucose delivered to the brain . Such a condition can damage parenchymal cells and disrupt blood-brain barrier (BBB) glucose transport [16,17] leading to oxidative stress [13,18,19], inflammation [20-22] and alterations in nitric oxide levels [23-25]. It is proposed that such a disruption of BBB permeability produces a “vicious circle” in which incremental reductions in cerebral perfusion accelerates the neurodegenerative process thus facilitating further drops in cerebral perfusion [11,26,27]. De la Torre [28,29] has long argued that the accumulating consequences of cerebral hypoperfusion precedes the appearance of clinical symptoms by many years. The goal of providing an effective treatment for AD has been elusive due to the complexity of the disease process and resulting inability to identify reliable biomarkers prompting competing hypotheses regarding etiology. In addition, some AD diagnostic indicators are present in other clinical conditions including vascular disease, frontotemporal dementia, Parkinson’s disease and HIV infection induced dementia, as well as normal aging [30-33]. These factors make drug development a very challenging task. However, a treatment designed to delay the onset of AD symptoms would maintain the patient’s quality of life, significantly reduce health care costs, and may be possible in the near future.
A step in this direction would be a treatment strategy designed to offset neuron losses by stimulating synaptogenesis in existing neurons and the formation of new functional neurons thus slowing disease progression. The neurotrophic agents capable of facilitating synaptogenesis and neurogenesis include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 [34,35]. To date BDNF has received the most attention . Our laboratory has focused on an overlooked neurotrophic factor, hepatocyte growth factor (HGF), and found it to be more potent than BDNF when activated by angiotensin IV (AngIV) and AngIVbased analogs . These analogs allosterically mimic dimerization/ activation, a prerequisite to binding at the Type 1 tyrosine kinase receptor Met [38,39]. This review initially describes current FDA approved drugs to treat AD, the renin-angiotensin system’s (RAS) role in memory formation, followed by a description of the HGF/ Met system. We conclude with details concerning the development and testing of AngIV-based analogs that activate the brain HGF/Met receptor system and show promise as anti-dementia agents in animal models of AD. We also detail the limitations of these molecules.
At present there are no adequate drug treatments available for AD. Current FDA approved drugs fall under two classes: 1) Cholinesterase inhibitors such as Razsadyne, Exelon, Cognex and Aricept that maintain a 75% market share [40,41]. These drugs are designed to disrupt the degradation of acetylcholine and thus extend the half-life and availability of this neurotransmitter acting at central cholinergic muscarinic and nicotinic receptors. Although the original research conducted on animal models was promising concerning the role of acetylcholine in memory consolidation and retrieval, the ability of such drugs to delay symptom in AD patients is modest at best . 2) Namenda (memantine HCl) received FDA approval in 2004 and acts as an N-methyl-D-aspartate (NMDA) receptor antagonist intended to limit glutamate excitotoxicity and resulting neuronal damage [40,43,44]. Namenda does appear to slow the progression of disease symptoms in some patients, particularly when given in combination with acetylcholinesterase inhibitors [45,46], but does not impact the underlying neuropathology of this disease.
In light of the “amyloid cascade hypothesis” considerable research effort has focused on the accumulation of insoluble brain Aβ protein as a basic cause of AD [47,48]. Thus, a major goal of drug development has been to attenuate and possibly block the production and deposition of Aβ1-42 [49,50]. Unfortunately Phase III clinical trials of these drugs were prematurely terminated when some mild-to-moderate AD patients evidenced reduced cognitive functioning as compared with patients receiving placebo [51,52]. This treatment approach falls short and modified and/or new strategies must be developed [53,54]. Another current approach is concerned with tau accumulations at synapses and the role of tau phosphorylation and acetylation [55,56]. If the chronic “cerebral hypoperfusion hypothesis” is correct then brain neuronal accumulations of Aβ1-42 and tau proteins must be considered downstream consequences rather than causes of AD . Further, a potential treatment strategy must include mechanisms to facilitate and maintain cerebral blood flow and encourage neuron replacement in damaged brain structures. As outlined in the next section the angiotensin system may offer such remedies.
The renin-angiotensin system is known for regulating blood pressure and body water balance as mediated by the octapeptide angiotensin II (AngII) acting at the angiotensin Type 1 receptor subtype (AT1; Figure 1). This system has received considerable attention with regard to the development of anti-hypertensive drugs. The RAS also promotes inflammation, oxidative stress, and tissue remodeling [57,58]), processes involved in what is now called the “neuronal inflammatory response” which is a key factor in neurodegenerative disease [59,60]. A contribution by AngII to memory formation was proposed some time ago ). Recent findings suggest that many of the memory enhancing effects originally attributed to AngII acting at the AT1 receptor subtype were due to the conversion of AngII to angiotensin III (AngIII) and then to the hexapeptide angiotensin IV (Ang IV) and it were AngIV activation of the AT4 receptor subtype that facilitated memory consolidation and retrieval [62-64]. This hypothesis is in agreement with the finding that angiotensin receptor blockers (ARBs) [65,66] and ACE inhibitors [67-69] improve cognitive processing in humans and animal models. Research interest in the AngIV/AT4 receptor system was further encouraged by the finding that AT1 and AT2 receptor antagonists failed to block learning and memory tasks in animal models . The genesis of this prediction rested with the notion that AT1 receptor agonists should facilitate memory while antagonists were proposed to interfere with memory processing. In fact central blockade of AT1 receptors by ARBs facilitated a variety of memory tasks in rats and mice ; while central administration of AngII impaired spatial memory . In contrast, a number of studies have noted AngIV and AngIV analog-induced facilitation of memory consolidation, retrieval and long-term potentiation (LTP), a phenomenon considered to be the building block of memory . Taken together these findings encouraged research interest in understanding the role of the AngIV/ AT4 receptor system in cognitive facilitation and this system’s potential value as a treatment for AD.
Figure 1: Angiotensin structures and synthetic pathway to produce biologically active ligands. The angiotensin synthesis pathway is presented indicating biologically active ligands (bold font), enzymes, and receptors involved in mediating related physiologies and behaviors. Angiotensinogen is converted to the decapeptide angiotensin I by renin. Angiotensin I is converted to the octapeptide angiotensin II by angiotensin converting enzyme (ACE). Aminopeptidase A (APA) converts angiotensin II to the heptapeptide angiotensin III that is converted to the hexapeptide angiotensin IV by aminopeptidase N (APN). Angiotensins II and III bind at the AT1 and AT2 receptor subtypes; while angiotensin IV binds at the AT4 receptor subtype. Antihypertensive drugs such as ACE inhibitors act to interfere with conversion of angiotensin I to the biologically active form angiotensin II, and angiotensin receptor blockers (ARBs) act as antagonists at the AT1 receptor thus preventing angiotensin II binding.
In the course of conducting research on this system we noticed a functional overlap between the AngIV/AT4 and HGF/Met receptor systems. These overlapping functions include facilitation of LTP and calcium signaling, memory enhancement, vascular angiogenesis, facilitation of blood flow and cerebroprotection, augmentation of dendritic arborization and synaptogenesis, and neurogenesis . This observation led to the hypothesis that AngIV and AngIV analogs may be interacting with the HGF/Met system. This neurotrophic system is described in the next section (Figure 1).
The plasminogen family member HGF, also known as “scatter factor”, acts at the Met receptor to stimulate mitogenesis, motogenesis and morphogenesis in a number of cellular targets including epithelial, endothelial and neurons [72-74]. This system has received considerable research attention related to its role in solid tumor cancers and possible therapies [75-77]. As the name implies HGF was originally isolated from the liver and shown to promote liver regeneration . The Met receptor is made up of disulfide bond-linked alpha (45 kDa) and beta (145 kDa) subunits  (Figure 2). Met’s molecular weight agrees with our estimated weight for the AT4 receptor calculated some years ago and suggests that they are the same protein. The alphachain of Met is extracellular while the beta-chain is transmembrane. HGF dimerization precedes binding to the Met receptor which then undergoes phosphorylation. Once phosphorylated the tyrosine residues of the beta subunit serve as docking sites for downstream signaling mediators including extracellular signal-regulated kinase (ERK) and the phosphatidylinositol-3-kinase (P13K) pathway  (Figure 2).
Figure 2: The structures and functions of the HGF/c-Met receptor system. (A) The structure of hepatocyte growth factor (HGF) includes a α-chain (69 kDa) of four Kringle domains and a β-chain (43 kDa) consisting of a serine proteinase homology (SPH) domain linked by disulfide bonds. (B) The Met receptor consists of a α-chain (50 kDa) and a β-chain (140 kDa) linked by disulfide bonds. HGF binds to Met resulting in tyrosine phosphorylation leading to a number of biological activities as listed. Nle1-AngIVand Dihexa act at the “hinge” region of HGF to facilitate dimerization which is a prerequisite to Met receptor binding and activation.
Given the overlapping functions listed above, members of our laboratory proposed that the AngIV/AT4 system closely interacts with the HGF/Met system [37,39,80,81]. This hypothesis was further supported by a search for a molecular target with a structure similar to AngIV. A partial match was seen with the protein angiostatin, and a related member of the plasminogen family HGF. This discovery suggested that AngIV-induced behaviors and physiologies could be mediated via the HGF/Met system. A major step toward understanding this relationship occurred when we determined that the AT4 receptor antagonist Norleual-AngIV (Nle-Tyr-Leu-(CH2-NH2)3-4-His-Pro-Phe) inhibited HGF binding to Met and HGF-dependent cell signaling, proliferation, invasion, and scattering . We further determined that Norleual-AngIV’s mechanism of action as a Met antagonist is by blocking HGF dimerization which, as indicated above, is a prerequisite to binding and activation of the Met receptor [82,83]. This dimerization process is dependent upon a short HGF domain located between its N-terminal and first kringle domain referred to as the “hinge region”  (Figure 2). The importance of this hinge region was confirmed by the synthesis and utilization of a hexapeptide mimic (Hinge: KDYIRN) that bound to HGF with high affinity and blocked HGF dimerization . The application of Hinge did not interfere with memory in normal functioning animals , a finding consistent with an earlier report that noted no impact on learning and memory in cognitively intact animals treated with AngIV and AngIV analogs . Given these results we hypothesized that AngIV analogs mimic this hinge region and behave as allosteric activators by emulating the change in HGF’s conformation that normally results from its dimerization. Imaging data from cultured neonatal rat hippocampal neurons indicated that Nle1- AngIV (Nle-Tyr-Ile-His-Pro-Phe; Figure 3) stimulates dendritic spine numbers and size, as well as overall dendritic arborization, suggesting a plausible mechanism for enhanced synaptic plasticity, connectivity among neurons, and facilitation of memory . HGF activation of the Met receptor has also been shown to mediate dendritic arborization and neurogenesis in cultured hippocampal neurons  and facilitate memory consolidation and retrieval in memory compromised animal models [87-90]. Elevated CNS levels of HGF have been measured in patients diagnosed with multiple sclerosis, Parkinson’s disease, amyotrophic lateral sclerosis and spinal cord injury [91-94]. Unfortunately these increases in HGF are not maintained with disease progression, and the hippocampal HGF/Met system appears to be down regulated in AD patients . Thus, the brain HGF/Met system appears to initially respond to neurodegenerative disease-induced injury by facilitating synaptic plasticity and neurogenesis; however these elevations in HGF are not sustained as the disease progresses (Figure 3).
In order to further understand the AngIV/AT4 system’s role in learning and memory and the minimal structural requirements necessary for AngIV to facilitate memory consolidation we combined radio-receptor binding techniques with behavioral testing. We began by evaluating C-terminal shortened AngIV compounds for binding affinity. We learned from previous work conducted in our laboratory that the N-terminus of the molecule is critical for binding and activity [96-98]. Substitution of valine with norleucine in the first position enhanced activity . Given this finding we began examining Nle1- AngIV and found that as C-terminal amino acids were removed Ki decreased from 3.59 × 10-12 for Nle1-AngIV to 4.89 × 10-9 M for Nle1- tripeptide (Nle-Tyr-Ile). Nle1-dipeptide (Nle-Tyr) had a Ki of 1.00 × 10-6 M indicating a substantial decrease in binding efficacy . We then prepared rats each with an intracerebroventricular (ICV) guide cannula in order to deliver this compound directly into the brain given their resistance in crossing the BBB. Following recovery from surgery we behaviorally tested these animals utilizing the Morris water maze task of spatial learning which has become one of the “gold standard” behavioral testing protocols for the evaluation of AD animal models . The icv delivery of the cholinergic muscarinic receptor antagonist scopolamine is frequently used to mimic the memory deficits seen in AD patients . Those rats pretreated with scopolamine followed by Nle1-AngIV, Nle1-pentapeptide, or artificial cerebrospinal fluid (aCSF) followed by aCSF, all performed equivalently and evidenced effective search strategies. Those groups pretreated with scopolamine followed by Nle1-tetrapeptide, or Nle1-tripeptide, required longer durations to locate the platform, however their search patterns were effective. The dipeptide Nle-Tyr was ineffective in facilitating successful search strategies. We next synthesized small molecules that were metabolically stabile using methods to protect against peptidase action while maintaining biological activity. Four strategies were used to protect the N-terminal: 1) acylation of the N-terminal amine; 2) substitution of a d-amino acid at the N-terminal position; 3) substitution of a non- α-amino acid (e.g., β-amino acid or ɣ-amino acid) at the N-terminal; or 4) use of a peptide bond isostere in place of the 1-2 peptide bond. These peptides may also contain an amide at the C-terminal to reduce the action of carboxypeptidases. Most recently we have been successful in creating a tripeptide analog (eg. Dihexa) with enhanced hydrophobicity and reduced hydrogen bonding potential that is orally active and maintains agonist activity at the HGF/Met receptor (Figure 3). Despite these improvements imparted to Nle1-AngIV to construct pharmacokineticly superior Dihexa, Dihexa should not be considered the optimal drug candidate. Additional refinements to its structure to limit both phase 1 and phase 2 hepatic metabolism and first pass clearance, to reduce metabolism by gastric enzymes and enhance oral bioavailability, and to diminish polar surface area and overall size to facilitate BBB penetrability are currently in progress.
These results encouraged the possibility that a clinically useful drug can be designed possessing oral efficacy, BBB penetrability, increased metabolic stability, coupled with facilitated cognitive functioning. Subsequent efforts yielded a family of Dihexa-based molecules possessing increased hydrophobicity, decreased hydrogen bonding potential, and increased metabolic stability. Dihexa and its analogs bind with high affinity to HGF, induce Met phosphorylation in the presence of subthreshold levels of HGF, stimulate hippocampal spinogenesis and synaptogenesis equivalent with HGF , and promote neurogenesis and cerebroprotection (data in preparation for publication). Treatment with the HGF antagonist, Hinge as well as a short hairpin RNA directed at Met, significantly inhibited these processes. These compounds penetrate the BBB in sufficient quantity to facilitate memory consolidation and retrieval in aged rats, and the scopolamine-induced amnesic rat model of AD, as measured employing the Morris water maze task of spatial memory .
Limiting side effects is of particular importance regarding angiotensin-based antihypertensive drugs given the documented problems of dry mouth, nausea and dizziness, muscle soreness, and diuresis that may occur with ACE inhibitors and ARBs. Each member of these classes of drugs is designed to reduce AT1 receptor activation and control hypertension. However, the AngII/AT1 receptor system influences multiple functions beyond blood pressure, including body water balance, control of vasopressin and oxytocin release and sexual reproduction and behavior, thus undesirable drug-induced effects are possible. Dihexa-based compounds do not interact with central or peripheral AT1 receptors, are highly target specific, exhibit little interaction with cardiac channel proteins and hepatic CIP isoforms, and reveal no acute toxicity following a 6x effective dose of Dihexa. More extensive safety studies are currently underway. These data predict that the greatest clinical impact may be in individuals with moderately compromised brain HGF/Met systems as present in earlyto mid-stage AD. The combined neuroprotective, synaptogenic, and neurogenic mechanisms activated by these compounds encourage the possibility that they may offer a treatment option for neurodegenerative and neuro-traumatic disorders beyond AD. Despite the potential to attenuate and possibly reverse deleterious molecular events common to many neurodegenerative diseases, we do not foresee this approach as a “cure” because the underlying etiologies will likely continue, albeit at a slower rate. We do believe that this approach can attenuate damage due to ongoing neurodegenerative processes and thus sustain the patient’s quality of life for additional months of reduced symptomatology.
Nerve growth factor was the first neurotrophic agent to be discovered followed by BDNF . Recently NT-3 and -4 have been isolated in the mammalian brain. HGF was originally extracted from liver and has now been identified in the brain [102,103]. Neurotrophins promote neural survival while substantial decreases in their levels have been measure in several neurodegenerative diseases. Thus, neurotrophins have been suggested as potential treatments for AD, Parkinson’s disease and other neurodegenerative diseases . Recently we have designed and synthesized AngIV-based small molecules that influence HGF dimerization and in turn Met receptor activation. These compounds are orally active and penetrate the BBB at sufficient levels to improve cognitive functioning in animal models of AD. The therapeutic value of this approach lies in its capacity to encourage the formation of new functional synaptic connections among existing neurons, encourage the replacement of damaged and lost neurons from available neural stem cell populations, and facilitate cerebral blood flow and neuroprotection. Such treatment outcomes would benefit patients afflicted with AD and possibly those suffering from other neurodegenerative diseases.
Drs. Wright and Harding are co-founders of M3 Biotechnology, Inc. and hold stock in this company which is involved in the development of AD and Parkinson’s disease drugs. No funds from M3 were used in the writing of this manuscript. Although the authors have financial interest in this biotechnology company we acknowledge no conflict of interest in the preparation of this review article which represents an impartial and accurate presentation of research findings. All animal experiments conducted in our laboratory and presented in this manuscript adhered to the Guidelines for the Care and Use of Laboratory Animals as required by the National Institutes of Health (NIH Publication No. 80-23), and these protocols were approved by the Washington State University Institutional Animal Care and Use Committee.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2017 All rights reserved. iMedPub Last revised : October 22, 2017